{"id":390308,"date":"2019-12-17T00:00:00","date_gmt":"2019-12-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2019-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-16T11:24:37","modified_gmt":"2026-04-16T11:24:37","slug":"dlsfim0004-2019-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2019-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Crohn&#8217;s Disease | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie \/ Eisai\u2019s Humira), together with newer therapies (i.e., Takeda\u2019s Entyvio, a\u00a0<abbr title=\"cell adhesion molecule\">CAM<\/abbr>\u00a0inhibitor, and Janssen\u2019s Stelara, an\u00a0<abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor), have transformed the treatment landscape for\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>, especially for moderate to severe disease, despite these drugs\u2019 efficacy limitations (e.g., patients lose response over time) and safety risks. The impending entry of several new therapies offering more-convenient formulations and\/or novel mechanisms of action (e.g., Galapagos \/ Gilead\u2019s filgotinib, TiGenix \/ Takeda\u2019s Alofisel, AbbVie\u2019s risankizumab and upadacitinib, Celgene\u2019s ozanimod) will further improve treatment and intensify market competition. In balance with these trends, the continuing generic erosion of conventional agents and the availability of less-expensive biosimilar\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors will constrain\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0therapy sales.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s\u2019 opinions of current treatment options (e.g., Remicade, Humira, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?<\/li>\n<li>What do\u00a0<abbr title=\"key opinion leader\">KOL<\/abbr>s think about emerging therapies (e.g., filgotinib, risankizumab, upadacitinib, ozanimod)? What impact will stem-cell therapy and oral therapies have on the\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0treatment algorithm?<\/li>\n<li>Which emerging agents are likely to be most successful in targeting\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-refractory patients and gaining uptake in the\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0market?<\/li>\n<li>How will the market evolve over the next ten years?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390308","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390308\/revisions"}],"predecessor-version":[{"id":576566,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390308\/revisions\/576566"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}